Praluent partners Sanofi and Regeneron have been battling for market share against Amgen’s Repatha in the PCSK9 class of cholesterol drugs, including by recently lowering their price. Now, the ...

The U.S. Supreme Court is breaking out the big guns to help make sense of Amgen and Sanofi's long-running PCSK9 patent feud. “The Solicitor General is invited to file a brief in this case expressing ...

In business parlance, a bolt-on acquisition is one in which the smaller company offers its acquirer strategic value. Swiss drugmaker Novartis’ recently announced $9.7 billion takeover of The Medicines ...

Drugmakers don't typically cut the prices of their products. Slow sales and market access challenges for Repatha (evolocumab) and its PCSK9 inhibitor peer Praluent (alirocumab), however, appear to ...

TRENTON, N.J. (AP) — The maker of an expensive cholesterol drug is slashing the list price, which should make it more affordable for patients. Amgen Inc. said Wednesday it is immediately cutting the ...

(Reuters) - Amgen Inc, looking to boost use of its potent cholesterol drug Repatha, has cut the medication's U.S. list price by 60 percent to $5,850, the U.S. biotechnology company said on Wednesday.

The maker of an expensive cholesterol drug is slashing the list price, which should make it more affordable for patients. Amgen Inc. said Wednesday it is immediately cutting the price of Repatha by 60 ...

Biotech giant Amgen (NASDAQ: AMGN) announced yesterday that the FDA has approved the Repatha Pushtronex system. This new system is a pre-filled, on-body medical device that allows for monthly, ...

In 2015, the launch of two new potent drugs to lower LDL-cholesterol (LDL-c) , Repatha (Amgen) and Praluent (Sanofi/Regeneron), sent shivers down the spines of payers. These drugs, the first of a ...

Sales of these heart disease drugs have been lackluster so far, but that may not be the case for too much longer. PCSK9 inhibitors lower cholesterol by increasing the number of bad cholesterol ...

TRENTON, N.J. — The maker of an expensive cholesterol drug is slashing the list price, which should make it more affordable for patients. Amgen Inc., which is headquartered in Thousand Oaks, said ...